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omitted in the differential diagnosis
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Abstract
Immune checkpoint inhibitors have emerged as a promising therapeutic option for metastatic cancers. However,
they have been associated with inflammatory adverse reactions in various organ systems. A recent article reported
a case of sudden bilateral hearing loss that occurred in a patient with metastatic melanoma being treated with
pembrolizumab. The authors attributed that complication to an autoimmune reaction secondary to the treatment.
This commentary discusses the importance of considering the diagnosis of leptomeningeal metastasis in patients
with metastatic melanoma who present with new cranial nerve deficits.
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Main text
We read with great interest the paper by Zibelman and
collaborators titled “Autoimmune inner ear disease in a
melanoma patient treated with pembrolizumab” pub-
lished in the Journal for ImmunoTherapy of Cancer [1].
The authors report a patient with widespread metastatic
mucosal melanoma who developed sudden bilateral
hearing loss while undergoing treatment with pembroli-
zumab. The episode of hearing loss was thought to be
an autoimmune inner ear event secondary to the use of
the immune checkpoint inhibitor.
Autoimmune inner ear disease (AIED) is defined as
rapidly progressive, usually asymmetric sensorineural
hearing loss [2]. Definitive tests do not exist to make this
diagnosis, but a proportion of patients with AIED have
antibodies against myelin P0, cochlin, β-tectorin and
HSP-70 [2]. The diagnosis is often based on a careful
history, physical examination, audiometry, laboratory
tests and diagnostic imaging, excluding other etiologies
of hearing loss.
Given that the patient had a melanoma of the anterior
skull base, we respectfully point out that another etiology,
namely leptomeningeal metastasis (LM), should have also
been considered in the differential diagnosis for this episode
of hearing loss. After carefully reading the article, it was not
readily apparent if the authors had ruled out that potential
cause. LM can complicate any cancer and is seen in up to
8% of all cancer patients. Melanoma is among the three
most common types of malignancies that cause LM [3]. Bi-
lateral sudden onset hearing loss has been described in the
context of LM in several reports, including a patient with
melanoma [4–6].
A high level of suspicion for LM must be kept in mind
for patients with metastatic carcinomas who present
with new cranial nerve deficits or other neurological
symptoms. The diagnosis of LM may be difficult to es-
tablish. Magnetic resonance imaging (MRI) of the brain
with gadolinium is the imaging study of choice. LM can
sometimes be microscopic and may not show on MRI.
In that case, lumbar puncture (LP) with demonstration
of malignant cells in the cerebrospinal fluid can confirm
the diagnosis [3]. It is unclear if the patient reported in
this article underwent an MRI of the brain or an LP
once hearing loss was confirmed.
It has been recently suggested that LM from melanoma
may respond to systemic targeted therapy and immune
checkpoint inhibitors [7]. This finding raises the possibility
that the hearing loss in this patient was, in fact, caused by
LM and the improvement in hearing resulted from a posi-
tive response to pembrolizumab and a decrease in disease
burden. However, as the authors pointed out, there exists
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a potential for checkpoint inhibitors to be associated
with AIED as they have been with other autoimmune
related neurologic complications. It is important to
remain vigilant about this possibility and to refer pa-
tients for appropriate testing and management if that
pathology is suspected.
Authors’ response
Matthew Zibelman, Natasha Pollak and Anthony J. Olszanski
We would like to thank Nader et al for their response to
our case report entitled “Autoimmune inner ear disease
in a melanoma patient treated with pembrolizumab.”
We agree that development of leptomeningeal disease
(LMD) is an important diagnostic dilemma for patients
with metastatic melanoma and should be high on the
differential in patients with this disease who develop
new cranial nerve deficits, including hearing loss. As the
authors point out, bilateral hearing loss has been de-
scribed in association with LMD, although this would be
quite rare, particularly without other detectable cranial
nerve deficits. Bilateral hearing loss would be theoretic-
ally more likely as an unintended, on-target side effect of
cross-reactive activated T-cells, though further reports
of incidence as anti-programmed death 1 (PD-1) path-
way drugs become more prevalent would be informative.
In our patient, he did not have magnetic resonance im-
aging (MRI) of the brain initially, but that was a function
of his claustrophobia. He refused MRI evaluation, thus
we proceeded with alternative assessments. Given his
presentation at that time with no other central nervous
system (CNS) deficits, clinical improvement with PD-1
blockade, and evidence of bilateral sensorineural hearing
loss, intratympanic dexamethasone injections were felt
to be both diagnostic and potentially therapeutic. The
patient did subsequently agree to have an MRI of his
brain 6 months later and it did in fact confirm an ab-
sence of LMD or other CNS disease. The patient re-
mains well, without evidence of progressive disease, now
14 months since discontinuation of the PD-1 inhibitor.
In this patient, the strong temporal association between
the development of bilateral hearing loss coincident with
anti-PD-1 therapy, with significant resolution of hearing
impairment upon initiation of intratympanic steroid ad-
ministration, strongly suggests that the hearing loss is
associated with anti-PD-1 therapy.
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